Results 41 to 50 of about 111,910 (294)

Pseudomyxoma Peritonei Secondary to Rupture of Intraductal Papillary Neoplasm of Pancreas (IPMN) [PDF]

open access: yesJournal of Clinical and Diagnostic Research, 2018
Pseudomyxoma peritonei is the intraperitoneal accumulation of a gelatinous ascites secondary to mucinous tumour rupture, more commonly associated with ovarian and appendiceal mucinous tumour.
Saurabh Kumar, Alok Kumar mittal
doaj   +1 more source

Laparoscopic appendicectomy for a large appendiceal mucinous neoplasm

open access: yes, 2021
We present the case of a 71-year-old male with long standing inflammatory bowel disease (IBD) who was diagnosed with an appendiceal mucinous neoplasm (AMN).
Francesco Colombo   +9 more
core   +1 more source

Epidermoid cyst in an intrapancreatic accessory spleen with abnormally high CEA level in cyst fluid: a case report

open access: yesAutopsy and Case Reports, 2022
Epidermoid cyst in an intrapancreatic accessory spleen is a rare benign lesion that is difficult to diagnose preoperatively. Cyst fluid analysis for biochemistry markers has been widely used to aid the diagnosis of pancreatic cysts.
Chun-hai Lo   +4 more
doaj  

Mucinous cystadenoma of the pancreas with predominant stroma creating a solid tumor

open access: yesWorld Journal of Surgical Oncology, 2005
Background Mucinous cystic neoplasm (MCN) of the pancreas is basically cystic epithelial neoplasm, unilocular or multilocular, occurring almost exclusively in women.
Ae Lee Won
doaj   +1 more source

PANCREATIC MUCINOUS CYSTIC NEOPLASM

open access: yesJournal of Cancer and Allied Specialties, 2016
-
Muhammad Fahd Shah, Fasial Hanif
doaj   +1 more source

Adjuvant radiotherapy in the treatment of invasive intraductal papillary mucinous neoplasm of the pancreas: an analysis of the surveillance, epidemiology, and end results registry [PDF]

open access: yes, 2011
Management and outcomes of patients with invasive intraductal papillary mucinous neoplasm (IPMN) of the pancreas are not well established. We investigated whether adjuvant radiotherapy (RT) improved cancer-specific survival (CSS) and overall survival (OS)
Gloor, Beat   +29 more
core   +2 more sources

Extracellular vesicle lipidomics liquid biopsy reveals systemic and tumor microenvironment metabolic reprogramming in ovarian cancer

open access: yesMolecular Oncology, EarlyView.
Extracellular vesicle (EV) lipidomic profiling of plasma and ascites from patients with high‐grade serous ovarian cancer and of ovarian cancer cell lines reveals enrichment of triglycerides (TGs), diacylglycerols (DGs), phosphatidylcholine (PCs), sphingomyelins (SMs), reflecting tumor metabolic reprogramming.
Shikha Rani   +9 more
wiley   +1 more source

Characterization of therapeutic antibodies targeting lymphatic and vascular resistance factor for the treatment of hypervascularized and highly metastatic cancers

open access: yesMolecular Oncology, EarlyView.
LVRF (lymphatic and vascular resistance factor) is a VEGFA splice variant upregulated in response to anti‐angiogenic therapy that fosters tumor adaptation through enhanced vascularization, lymphangiogenesis, and metastatic dissemination. Targeting LVRF with fully human neutralizing antibodies disrupts these processes and limits resistant tumor growth ...
Marion David   +12 more
wiley   +1 more source

Radiomics advances in the evaluation of pancreatic cystic neoplasms

open access: yesHeliyon
With the development of medical imaging, the detection rate of pancreatic cystic neoplasms (PCNs) has increased greatly. Serous cystic neoplasm, solid pseudopapillary neoplasm, intraductal papillary mucinous neoplasm and mucinous cystic neoplasm are the ...
Kuan-Zheng Mao, Chao Ma, Bin Song
doaj   +1 more source

Helicobacter pylori is undetectable in intraductal papillary mucinous neoplasm

open access: yes, 2016
Background: About half of the world population is infected with Helicobacter pylori (H. pylori), a bacterium associated with gastric cancer and considered to be a risk factor for pancreatic ductal adenocarcinoma.
BAĞCI ÇULÇİ, PELİN   +1 more
core   +1 more source

Home - About - Disclaimer - Privacy